Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

J. MINARIK, V. SCUDLA, J. BACOVSKY, M. ZEMANOVA, T. PIKA, M. ORDELTOVA, K. LANGOVA
2010 Neoplasma (Bratislava)  
We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI < 2.8% (median overall survival 30 vs 12 months) with a borderline significance (p = 0.06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of
more » ... l drugs. In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10months, p = 0.015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in all MM patients.
doi:10.4149/neo_2010_01_008 pmid:19895166 fatcat:vtmuy4xo65hypmbhc5lus32nki